文献速递前列腺癌

磁共振成像前列腺癌筛查:Göteborg 2试验第二轮结果

Prostate Cancer Screening with Magnetic Resonance Imaging: Results from the Second Round of the Göteborg Prostate Cancer Screening 2 Trial.
PubMed 文献 · Eur Urol Oncol · 2021-09-25

Göteborg 2试验评估PSA升高后行MRI的前列腺癌筛查策略,本轮对首轮MRI阴性或活检阴性者间隔2年复筛。376名复筛者中89%MRI阴性,靶向活检检出14例癌(9例GG1,5例GG2-3);仅2例PI-RADS≥3者按PRECISE进展。结论认为MRI阴性者2年间隔安全,但PI-RADS 4/5且活检阴性者需更密切随访。

要点

  • MRI阴性者2年复筛间隔安全, interval癌中仅2例GG5。
  • PI-RADS 4/5且首轮活检阴性者应缩短随访间隔。
  • 复筛人群89%MRI阴性,靶向活检癌检出以低级别为主。

核心结论

  • 对MRI阴性男性,2年筛查间隔似乎是安全的。
  • 对PI-RADS 4和5且活检阴性的男性,应更密切随访。

研究设计与样本

  • 首轮PSA升高且MRI阴性或活检阴性者2年后复筛,共474人接受第二轮筛查。
  • 复筛MRI由两名放射科医生按PRECISE重新判读,interval癌通过区域癌症登记链接识别。

主要发现

  • 474名复筛者中19%第二轮PSA不高而未进一步检查。
  • 剩余376人中89%MRI阴性。
  • 靶向活检检出14例前列腺癌:9例GG1,5例GG2-3。
  • 第二轮确诊且PI-RADS≥3者中,仅2例(GG1)按PRECISE进展,其余稳定。

关键数值与推荐

  • MRI阳性定义为PI-RADS评分≥3,行靶向活检。
  • MRI阴性或活检阴性者2年后重新邀请筛查。

临床怎么用

  • PSA升高后MRI阴性者可采用2年间隔复筛。
  • PI-RADS 4/5但活检阴性者应缩短随访间隔并密切监测。

局限性

  • 复筛样本量有限(474人),事件数少。
  • interval癌通过登记链接识别,可能存在漏报。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Göteborg 2 prostate cancer (PC) screening (G2) trial evaluates screening with prostate-specific antigen (PSA) followed by magnetic resonance imaging (MRI) in case of elevated PSA levels. OBJECTIVE: To assess the safety of using a 2-yr interval in men who were previously screened positive with PSA but had negative MRI or positive MRI with a negative biopsy. DESIGN, SETTING, AND PARTICIPANTS: A total of 61 201 men aged 50-60 yr were randomized and 38 366 were invited for screening (years 2015-2020). Men with positive MRI (Prostate Imaging Reporting and Data System [PI-RADS] score ≥3) were scheduled for targeted biopsies. Men with negative MRI or negative biopsies were reinvited after 2 yr. Round 1 and 2 MRI scans (PI-RADS ≥3) of men not diagnosed with PC in round 1 were re-read and classified according to Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) by two radiologists. Interval PCs (detected outside the program before invitation to round 2) were identified by linking to the Regional PC Registry. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Tabulation of overall detection of PC was done. RESULTS AND LIMITATIONS: Between October 2017 and June 2020, 474 men with round 1 elevated PSA and MRI underwent a second screening. Of those, 19% had nonelevated PSA in round 2 and were not examined further. Of the remaining 376 men, 89% had negative MRI. Targeted biopsies yielded 14 PCs: nine grade group (GG) 1 and five GG 2-3. In men with PI-RADS ≥3 and PC diagnosed in round 2, only two (GG 1) progressed according to the PRECISE criteria and the remainder were stable. Ten interval PCs were diagnosed: seven GG 1, one GG 2, and two GG 5. The two GG 5 PCs were PI-RADS 4 and 5 with negative round 1 biopsy. CONCLUSIONS: A 2-yr interval seems to be safe in men with negative MRI, while men with PI-RADS 4 and 5 lesions with negative biopsies should have a closer follow-up. PATIENT SUMMARY: In prostate cancer screening, a 2-yr follow-up seems to be safe if magnetic resonance imaging did not show highly suspicious findings.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Wallström J, Geterud K, Kohestani K, et al. Prostate Cancer Screening with Magnetic Resonance Imaging: Results from the Second Round of the Göteborg Prostate Cancer Screening 2 Trial. Eur Urol Oncol. 2021. PMID: 34580053. doi:10.1016/j.euo.2021.09.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。